Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix presented new individual-patient PK/PD data at ACR Convergence 2026 showing that higher single doses of PRX-115 kept plasma uric acid below the 6.0 mg/dL therapeutic target for extended periods. At the 36 mg dose, mean uric acid stayed below target for up to 12 weeks after a single infusion, with PRX-115 plasma levels remaining measurable for up to 85 days, supporting less frequent dosing.
Key figures
- Drug Name
- PRX-115 (recombinant PEGylated uricase)
- Phase Of Trial
- Phase 1 (single ascending dose); Phase 2 RELEASE ongoing
- Urate target
- 6.0 mg/dL
- Phase1 cohorts
- 18 mg, 24 mg, 36 mg (6 participants per cohort)
- Release topline
- second half of 2027
- Phase2 release arms
- five arms of 30 patients each, fixed 36 mg dose
- Prx115 detectable days
- up to 85 days
- Duration below target 36mg
- up to 12 weeks after a single infusion
- Us uncontrolled gout patients
- 180000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.